Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialSara A. Hurvitz, Javier Cortés, Joanne Wing Yan Chiu et al.|The Lancet|2022Cited by 664
Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Sara A. Hurvitz, Javier Cortés, Roberto Hegg et al.|Cancer Research|2023Cited by 12
Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)William Jacot, Erika Hamilton, Seock‐Ah Im et al.|Clinical Cancer Research|2025Cited by 2